The campaign aims to demonstrate the direct link between proactive parasite management and flock performance, while also providing tools for vets to engage farmers in conversations around worm control on-farm.
Fiona Hutchings (pictured), ruminant technical manager at Elanco Animal Health, said: “The Better Butt campaign encourages vets and farmers to work together to strategically plan mid- to late-season break doses and quarantine treatments, using the newer group wormers, such as Zolvix, to minimise worm burdens and support healthy growth.”
Fiona says the campaign advises farmers to move away from solely relying on visible signs of worm burdens before taking action, because lamb performance has already been compromised by the time visible signs are present: “Even the best stockman, or experienced sheep person, will struggle to spot an early worm burden, and by the time it’s visible, the burden is usually high.”
“Reductions of up to 50% in growth rates can occur before visible symptoms appear1, resulting in extended finishing times and higher feed demands.”
The campaign uses a traffic light system to help farmers understand worm burden impacts and encourages treatment interventions when animals tip into the amber zone.
“When lambs have a low worm burden, they’re in what we call the green zone, which means they have enough energy for both maintenance and growth.
“However, when this burden increases and they tip into the amber zone, this is when you’ll start noticing changes in the time taken for lambs to finish as worms begin to damage the gut meaning the lambs can’t utilise their feed as well.”
Fiona added: “Many sheep farmers are already doing a brilliant job of managing their stock, but we want to show them that there could be an opportunity to unlock more potential from their flock.”
https://farmanimal.elanco.com/en_gb/sheep/sheep-worms/zolvix-worth-every-penny
ParaProtect offers bitesize interactive learning modules, each taking 20 to 30 minutes to complete.
The programme is open to all practice staff, from vets and nurses to client care teams, and aims to advance parasitology expertise and build further confidence in risk-based parasite protection.
Elanco says each module includes expert insights, real-world case studies and practical advice that can be applied immediately in practice.
The first module: ‘Parasite Control in a One Health World’, explores the wider implications of parasite control, including risks to public health from parasites, and consideration for the environment when selecting and using parasiticides.
Later modules will cover topics such as the impact of climate and travel on parasite spread, myth-busting, emerging risks, and how to improve client communication and compliance.
Jacqui Skelly, Head of Veterinary Technical Services, UK & Ireland at Elanco, said: “Parasitology is a field of medicine that most vets are practicing many times a day, yet it’s easy to neglect when it comes to CPD.
“As parasite risks evolve alongside climate and behavioural change, there’s growing demand for CPD that reflects current science and supports evidence-based decision making in practice.
"With ParaProtect, we aim to service that need with a different kind of programme.
"It’s short, practical, relevant and designed to be used straight away in the consulting room.
"It has principles of responsible use of parasiticides built into the core of the learning, and helps teams move beyond routine treatment to deliver advice that protects pets and their families, especially as summer travel increases parasite risks.”
https://my.elanco.com/en_gb/campaign/pet/paraprotect
Photo: www.depositphotos.com
Zenrelia is a new JAK inhibitor which Elanco says provides visible itch relief which lasts 24 hours, from the first dose.1
The company points to a head-to-head study with over 330 dogs across 25 vet clinics, in which Zenrelia was shown to get 45% more itchy dogs back to normal than Apoquel (oclacitinib).1
Elanco says its once-daily dosing may also improve treatment compliance over twice-daily alternatives.
The company also says that Zenrelia has a cost benefit too, presumably meaning it's cheaper than alternatives.
Zenrelia can be given long term with commonly used medications, including vaccines, antibiotics, parasiticides and NSAIDs.
Elanco UK & Ireland General Manager Matthew Frost said: “With this treatment, we’re looking at happier dogs and their owners, and a more rewarding experience for vets.”
www.zenrelia.co.uk
Reference
The panel will present the latest information on the prevalence of this zoonotic disease, review prevention strategies, and highlight the significance of cystic echinococcosis in humans.
The panelists are:
Dr Carolyn Kyte MRCVS (pictured), Elanco's UK Technical Consultant said: “We are concerned about potential changes in the distribution of Echinococcus granulosus in the UK and a subsequent change in zoonotic risk.
"We are hoping this cross-disciplinary discussion will provide Congress and Expo attendees with the latest insights the profession needs to allow individual, risk-based parasite control in dogs.
"The responsible use of parasiticides needs a true One-Health collaborative approach.”
With 2024 support payments for farmers in England now at half former levels and significant changes to subsidies for farmers in Scotland and Wales set to come into play next year, Elanco says effective flock health management to maximise efficiency and performance within flocks has become increasingly important.
Elanco's Ruminant Technical Consultant, Matt Colston MRCVS said: “Policymakers recognise the importance of animal health and welfare for better productivity and are putting an increasing onus on vets to deliver improvements, for example via the Animal Health and Welfare Pathway (AHWP).”
“Its crucial vets have the knowledge and confidence to support sheep clients on important flock health issues, with worming programmes high up on this agenda.”
"By developing farm-specific worm control strategies and working closely with clients to better monitor worm burdens, you can help achieve immediate flock performance benefits and manage the longer term risks of anthelmintic resistance on that farm.”
Elanco says that by dosing lambs with its newer Group 4 wormer, Zolvix, at the right time during the mid to late grazing season, farmers can clear out any resistant worms that have survived previous treatments and see an uplift in daily liveweight gain as a result.
Matt added: “We shouldn’t wait for problems to manifest.
"By the time wormer groups have stopped working, or clinical signs of worms are visible, damage is already done; regular monitoring and early intervention is a better option.
“More farmers are Faecal Egg Counting (FEC) but many are unsure how best to go about it.
“A practical demonstration of how to collect samples, and what to collect from which animals, is often the best way to show how easy FEC can be.”
“Farmers can be cautious about change, but by taking small steps and consistently offering sound, practical advice, vets can help farmers adopt more sustainable worm control strategies and improve margins in sheep production.”
During the webinar, panel contributors Fiona Lovatt (past president of Sheep Veterinary Society), Jenny Hull (Black Sheep Farm Health, Northumberland), Lesley Stubbings OBE (lead member of SCOPS and independent sheep consultant), and Phillippa Page, (independent sheep vet consultant) will discuss:
The first 250 delegates to sign up will receive a copy of the In Practice supplement as well as a Zolvix notebook and pen.
https://app.livestorm.co/elanco-animal-health/flock-health-in-practice-webinar
Game players have to 'catch' falling symbols marked with a '+' or the Credelio Plus ingredients, milbemycin oxime and lotilaner to win points, and avoid ones with fleas, ticks and worms, which lose points.
In addition to the £50 vouchers, there are goody packs for four runners up each month.
William Hawker, Parasiticides Marketing Manager at Elanco Animal Health said: "We are excited to showcase our novel new game at BVA Live with this exciting drop and offer all attendees the first chance to play Plus Plummet and win some great prizes by topping the leaderboard every month."
To play the game, visit: https://www.myelanco.co.uk/brand/plus-plummet
Incidentally, if you're at BVA Live, you're invited to join Elanco at the Exhibitor Showcase Theatre tomorrow from 09:00-09:50 for ‘Parasitology: Testing Times? Navigating the current challenges in practice’.
Cat Henstridge (BVSc MRCVS, small animal vet) will be interviewing Ian Wright (head of ESCCAP) and answering questions on everything from when to test, when to treat and how to communicate with pet owners about choice and the parasiticide treatment options available.
Photo: Elanco launches Plus Plummet at BVA Live
This, says the company, suggests that infection could be more common among seemingly healthy dogs than vets or owners realise, which may mean there is a greater risk of perioperative bleeding caused by the coagulopathies associated with A. vasorum2 than previously thought.
Elanco says another recent study indicates that there may be a bigger environmental risk for dogs than previously thought, too.
In the study, by Robbins et al, L3 larvae of A. vasorum and Crenosoma vulpis arising from the gastropod intermediate host were found to be immediately infective to dogs and remain so for up to eight weeks, meaning that dogs may only need to lick the molluscs’ slime to be at risk of infection.3
Elanco says this new data means A.vasorum should be added to many differential diagnosis lists, and that pre-operative testing could also be wise.
Jenny Helm, BVMS Cert SAM Dip-ECVIM CA FHEA MRCVS, European Specialist in Small Animal Internal Medicine, said: “Owners need to be aware that healthy dogs could be silently carrying and spreading the disease and that asymptomatic carriers could develop clinical signs at any time.
"They need to be aware that dogs don’t necessarily have to eat slugs and snails to become infected, as recent evidence suggest that other routes of transmission are possible.” To improve data on the prevalence of lungworm, Elanco has developed a version of its lungworm map specifically for veterinary surgeons, where you are invited to upload your cases (including asymptomatic positive cases: www.lungwormmap-vet.co.uk.
For those practices which want to run lungworm awareness campaigns in their area, Elanco has a how-to guide, posters and artwork available to download at www.myelanco.co.uk.
References
Leading industry experts including Faye Murch from Kingsgate Nutrition, Eric Nadeau, Elanco Global Pig Vaccine Advisor, veterinary consultant Daniel Parker and Francesc Molist from Schothorst Feed Research will share their learnings on alternative approaches to managing PWD, including vaccination.
Jack Fellows from Elanco Animal Health says that with 90% of producers using their vet as their first port of call when it comes to PWD1, it is vital they start to encourage producers to consider an alternative prescription to zinc.
He said: “Producers must start to prepare now to avoid being forced to turn to antibiotics when zinc is no longer an option.
"Vaccination will become an increasingly important component of PWD prevention. Amongst other topics on mastering piglet gut health, the seminar aims to support knowledge on the application of in-water vaccines to ensure appropriate and effective use.”
Jack says that while vaccination may appear costly in comparison to zinc oxide, it offers a good return on investment: "Piglets can be vaccinated from 18 days of life, so they are protected from the pathogen at weaning, and we are seeing a growing number of UK herds using vaccines as part of their PWD prevention strategy.
"Farms using the Coliprotec vaccine are no longer using in-water medication to control scours. They’re also noticing that piglets are eating more, and that they’re achieving an extra 2kg of slaughter weight2 while reaching market weights seven days sooner3.”
To register for the event, visit: https://www.myelanco.co.uk/pub/swine-seminar-registration
Credelio Plus is a palatable, chewy, monthly tablet which contains milbemycin oxime for the control of the gastrointestinal nematodes: hookworm (L4, immature adult (L5) and adult Ancylostoma caninum), roundworms (L4, immature adult (L5) and adult Toxocara canis and adult Toxascaris leonina) and whipworm (adult Trichuris vulpis). Also for the prevention of angiostrongylosis by reduction of the level of infection with immature adult (L5) and adult stages of Angiostrongylus vasorum (lungworm) with monthly administration. Also for the prevention of heartworm disease (Dirofilaria immitis).
Credelio Plus also contains lotilaner for the immediate and persistent treatment of ticks (Dermacentor reticulatus, Ixodes ricinus, Rhipicephalus sanguineus and I. hexagonus) and flea (Ctenocephalides felis and C. canis) infestations in dogs.
Credelio Plus is licensed for puppies as young as 8 weeks and weighing 1.4 kg or more.
Tina Hunt, General Manager of Elanco UK/Ireland said: "The launch of Credelio Plus represents another exciting evolutionary leap for Elanco’s parasiticide portfolio.”
Cat Henstridge MRCVS, otherwise known as 'Cat the Vet' said: "As a companion animal vet, one of the common challenges I see from pet owners is the need to remember and administer multiple treatments to cover a variety of parasites.
"So a simple, easy-to-remember treatment will be welcomed by my clients who need a combination solution to protect their dogs from ticks, fleas and worms.”
To mark the launch of Credelio Plus, Elanco is inviting vets and nurses to register for an online event at which the astronaut Major Tim Peake will talk about the lessons he’s learnt about leadership and teamwork, performing in high-pressured environments and the future of medicine and science. He'll be followed by Cat Henstridge, who will give a presentation about the power of wider veterinary teams working ‘better together’ to support each other, and how practices can start to reconnect with their clients following lockdown.
Lepha McCartan, BVetMed MRCVS, Veterinary Technical Consultant, Elanco Animal Health, will also speak about Elanco’s ongoing work within the parasite space. There will also be a live Q&A where attendees can put questions to the panel.
To sign up for the launch event, visit https://www.myelanco.co.uk/brand/credelio-plus-launch-registration
Jack Fellows, Elanco swine sales leader, said: "With the potential zinc oxide restrictions coming into place next year, it’s crucial that vets work with their farmers to start trialling alternative PWD prevention strategies now, while the use of zinc is still permitted.
“Keeping PWD at bay going forward will require a multifaceted approach to piglet management. Gradually reducing the level of zinc oxide, while simultaneously incorporating alternative preventive techniques, will reduce the likelihood of problems arising during this transition.
“It’s far more convenient to have the vaccine in a 200 head dose, rather than the current pack size that offers 50 treatments. This will greatly cut down the time required to dilute and stabilise multiple individual packs, while helping to minimise any margin of error during administration."
Research has shown over 90% of farmers1 would head to their vet as the first port of call when it comes to advice on treating PWD.
“It’s crucial that vets are aware of all the preventive tools and options for managing the disease as over half of farmers surveyed2 also said they would treat PWD with antibiotics, which is obviously something we’re trying to steer away from as an industry, and why vaccines play such an important role going forwards.
“The Coliprotec vaccine is proven to prevent against these issues, delivering healthy pigs that reach a heavier market weight up to 7 days earlier3, while substantially reducing the in-nursery use of antibiotic treatments."
To mark the launch of the new 200 dose pack size, Elanco is offering veterinary practices the chance to buy five packs for the price of four, a total of 1000 doses, through their wholesaler.
For more information, contact Jack Fellows at jack_michael.fellows@elancoah.com or call 07771 798157.
Elanco says Baycox Iron offers a time-saving flexible dosing treatment which complements the company’s existing piglet gut health portfolio.
Louise Radford, marketing manager at Elanco, said: "By treating piglets at two or three days old, it’s possible to allow enough exposure to the coccidiosis parasite to enable them to develop natural immunity, while preventing any damage to the gut caused by subclinical and clinical coccidiosis which leads to poor growth and low weaning weights.
"By combining treatments, it's possible to limit the number of times they are handled, which in turn reduces stress and enhances growth”.
Elanco also makes the Coliprotec vaccine against post weaning diarrhoea (PWD).
Louise added: “As farmers and vets prepare for the removal of zinc oxide as a treatment option next year, focusing on gut health throughout all stages of development has never been more crucial.
For more information, contact your Elanco pig team specialist or visit https://www.myelanco.co.uk/cpd/swine/hub.
The company has launched a ‘Vet Show CPD hub’ (www.myelanco.co.uk/brand/lvshub) which, as the name suggests, hosts a variety of CPD presentations accompanied by competitions, including one in which you can win £250 Amazon vouchers.
The CPD hub also has information about the company's range of products, including Credelio, Neptra, Galliprant and Advocate.
From the 10th November, Elanco will also host a series of webinars in partnership with the London Vet Show (https://london.vetshow.com/elanco):
As a thank you, the first people to sign up to the webinars will also get an ‘Elanco Vet Show CPD at home’ box, with goodies to enjoy while tuning into the virtual event.
Tina Hunt, managing director of Elanco UK/Ireland, said: "2020 has been a year of incredible change, which has included our global acquisition of Bayer Animal Health. While we remain physically separated, it is important to us that we continue to engage with our veterinary friends and customers to maintain the sense of community that networking events can be so vital in nurturing.
"We also wanted to take this opportunity to recognise the commitment of veterinary professionals across the UK and thank you for your ongoing support and dedication at the forefront of animal care. Our entire team look forward to you joining us for three exciting webinars and to hosting you on our hub."
The event is being hosted by Luke Gamble as part of the company's ‘Advocates of Knowledge’ series, and there are £400 worth of prizes to be won:
Advocate Senior Brand Manager Vicky McAlister said: “We want to ensure that we’re delivering CPD in an engaging way, so that vets are still able to upskill in these areas, whilst also being able to engage with other vets in the industry, which is especially important given current times.
"Following the success of the first event, we’re pleased to be back again to host another and are committed to continuing to support CPD progression.”
To register for the event, visit: https://www.eventbrite.co.uk/e/113870170746
The aim of the ‘Advocates of Knowledge’ CPD lungworm modules is to help vets assess the lungworm risk in their area, recommend prevention and treatment regimes and also to communicate effectively with clients as the UK emerges from lockdown.
In the first module, Dr Jenny Helm, European Specialist in Small Animal Internal Medicine and Senior Veterinary Clinician at the University of Glasgow, tackles questions about lungworm post lockdown, including whether or not pets are at greater risk as a result of changes in their owners' behaviour caused by the pandemic.
The second module, from Dr Simon Tappin, European and RCVS Recognised Specialist in Small Animal Internal Medicine, and Head of Medicine at Dick White Referrals (pictured right), will take the form of an interactive case-based discussion on lungworm. He will use clinical cases to talk through presenting signs, and how to approach investigation of these cases, as well as looking at treatment and prevention strategies.
Vicky McAlister, Senior Brand Manager for Advocate, said: “During lockdown, dog owners have modified their behaviour (including spending more time outdoors with their dogs), and this may have affected the risk of dogs becoming infected with lungworm. So we’re very pleased that, together with our experts, we’re launching informative, engaging and relevant CPD lungworm modules for vets, to help provide them with the information needed, and importantly to encourage communication with dog owners regarding this important subject matter”.
You can sign up for the CPD modules here - https://advocatesofknowledge.vettimes.co.uk.
The award was due to be presented at the association's annual shindig in March, which was cancelled due to the coronavirus pandemic.
VMA Awards chair, Claire Edmunds, said: “This years’ winners will still get their moment of glory on stage next March at the rescheduled event. We can also announce that the event is likely to include some additional categories to recognise campaigns and initiatives undertaken during the COVID-19 pandemic.”
Carlos Michelsen, managing director of award sponsor, CM Research, added: "Thanks to the continued success of Cytopoint, Zoetis achieved highly commended status. But it was Elanco that came in as award winners, with their novel veterinary pharmaceutical product Galliprant taking the crown. Congratulations to Elanco!"
Rebecca Bryant, Elanco’s marketing manager for Pet Health Therapeutics (pictured right), said “Elanco is delighted to be recognised by the veterinary community with this prestigious award for Galliprant. The UK team is proud to be part of the launch of this innovative, first-in-class product which has already enriched the lives of thousands of pet owners and their dogs living with osteoarthritis. It’s fantastic to hear from vets that managing OA with Galliprant has already made a positive impact on their practices.”
Zoetis product manager, Allison Henry said: “We are very proud to come such close second in this award category as it is a true testament to the lasting innovation Cytopoint has brought to our industry, customers and pets. At Zoetis, we always strive to develop innovative new medicines for the veterinary industry and we are thrilled to see how Cytopoint has done just that.”
The Osurnia Ear Health Hub includes information about the treatment of canine otitis externa from dermatologists Sue Paterson and Natalie Barnard, advice about responsible antibiotic use, expert tips for vets to use in the consulting room and dog owner educational materials that veterinary staff can use in practice and online. It will also include a podcast interview with Sue.
The hub also provides information, videos and research about Osurnia.
Elanco Animal Health UK Marketing Manager, Rebecca Bryant said: "We know all too well the challenges vets face when treating canine OE and the significant impact the condition has on the quality of life of both the dog and the owner.
"The Osurnia Ear Health Hub is a new disease resource hub on MyElanco, which provides helpful resources for veterinary professionals looking for answers or to enhance their understanding of the disease. We hope that with more easily accessible information, this will help vets to treat OE cases and communicate with their clients."
Visit the canine ear health hub at: www.myelanco.co.uk
Whilst on the subject of information resources, this one has come to my attention. It's a list of other veterinary blogs and resources: https://blog.feedspot.com/veterinary_blogs.
The divestment is expected to be concluded in mid-2020, and Bayer intends to exit its stake in Elanco over time.
Bayer says that combining Elanco and Bayer Animal Health will create the number two animal heath company, with top three positions across a broad range of species and geographies. It also enhances Elanco’s portfolio of leading global brands and bolsters its innovation capabilities and R&D pipeline.
Jeffrey N. Simmons, president and chief executive officer of Elanco, said: "Combining Elanco’s strong relationship with veterinarians and Bayer’s leadership in retail and e-commerce will ultimately benefit all our customers. We look forward to joining our complementary portfolios and capabilities to build a fully focused animal health company, providing a sustained flow of innovation for farmers, veterinarians and pet owners."
This only affects batch number C967336A, expires before 07/2020. Any other batches of Tylan 200 Injection are not affected and may continue to be distributed.
Elanco is contacting wholesale dealers and veterinary surgeons to examine inventory immediately and quarantine products subject to this recall.
For further information regarding the recall, please contact Ms Victoria Haslingden 01256 779519 or email elanco_orders@lilly.com
Galliprant is a first in a class of drugs called piprants, or non-COX-inhibiting prostaglandin receptor antagonists (PRAs), which specifically target the EP4 receptor largely responsible for OA pain and inflammation1,3 without interfering with other prostanoids and receptors, thereby minimising the impact on gastrointestinal and kidney homeostasis.1,4
According to Elanco, the main benefit of the new drug is that it can be given in the earlier stages of the disease; from first diagnosis in fact. Speaking at the London Vet Show in 2018, Dr Kristin Kirkby Shaw, Surgeon and Rehabilitation Specialist at the Animal Surgical Clinic of Seattle, said: "…being much more targeted, it makes us feel more comfortable starting this product in an earlier stage of osteoarthritis."
In the target animal safety study, Galliprant was well-tolerated over 9 months at doses equivalent to 15 times the target dose.5 Kristen said: "I challenge anyone to think of another product that has been given in a safety study at that high of a level for that duration of time."
The efficacy of Galliprant was demonstrated in the field study at the licensed target dose of 2mg/kg body weight, with treatment success seen by owners in their dogs at home, and confirmed by vet assessment.2 Owners saw statistically significant improvements in pain severity and interference with daily activities vs placebo at days 7, 14, 21 and 28.2
For more information, visit www.galliprant.co.uk. You can also watch Dr Kristen Kirkby Shaw's London Vet Show presentation and other expert opinion here.
References:
The five-part series, which is hosted on Elanco’s customer portal MyElanco.co.uk, covers topics including managing social media communities, how to build a presence using social media advertising and how to respond to new regulations around personal data.
According to a report on Bloomberg, Facebook is reported to be on track to have 32.6 million regular users in the UK despite its falling audience of younger users. Meanwhile Instagram's UK user base was believed to be 16.7 million at the end of 2017. Hence why 81% of small and medium businesses are reported to use some kind of social platform.
Elanco Customer Experience Manager Matthew Rowe said: "The global popularity of social media sites means people now expect businesses to have a social media presence and veterinary practices are no different.
"More veterinary practices are launching business profiles, recognising how vital it is to have a social presence so they can engage with their clients outside of the consultation room. But we realise that it can seem like an intimidating and complex process.
"The workshops have been created to help more vet practices get started with social media and gain more confidence to make the most out of it for the benefit of their business."
To watch the videos, register at MyElanco.co.uk and visit: https://www.myelanco.co.uk/CPD/video-workshop-part1
Elanco says OA is a condition which is estimated to affect one in four dogs, but it is often labelled by owners as "just old age". This, says the company, may lead to missed diagnosis and dogs not receiving the care they need.
To try and help address the issue, Elanco has partnered with the founder of Canine Arthritis Management, Hannah Capon and veterinary communications consultant, Zoe Belshaw to produce a number of online and in-practice tools.
The first of these is a worksheet to help veterinary surgeons explain the impact of OE on the client's dog, both in and outside the home. It provides a template for creating a tailored management plan and a guide to the home adaptations owners can make to help improve their dog's quality of life.
The company has also produced a infographic fact sheet which explains the subtle signs of OA, designed for vets and nurses to use as part of their regular interactions with owners.
Elanco has also designed a range of digital materials for veterinary practices to use on their websites and social media feeds to increase awareness of the condition among their online communities.
Hannah Capon said: "Arthritis affects every dog differently – a dog may be full of life but lame, quiet, unenthused and slow to move, or somewhere in-between.
"Home management needs to be tailored to each dog’s needs and adapted in the same way it would be for a person, to prolong life and minimise pain and further injury."
Lastly, Elanco has also produced a film in which Zoe Belshaw gives advice about the language and strategies veterinary surgeons can use to help improve communication with dog owners about OA.
Zoe said: "My research identified that many owners do recognise their arthritic dog has a problem before it’s diagnosed. Many will have seen that their dog is stiff, or ‘slowing down’ but they may not associate this with lameness, or pain.
"That’s why vets, nurses and practices play a critical role in raising awareness of how the condition impacts dogs every day."
To access the suite of assets visit: www.myelanco.co.uk
The NSAID's new indication is in addition to its existing license for acute pain and inflammation.
Elanco points to research it carried out which found that over a six week period, owners saw a visible improvement in their cats' performance of daily activities. There was also a 50% reduction in owner-assessed pain and disability (significantly greater than seen in the placebo group)1.
The company says the product, which is administered once-daily as a small flavoured tablet, is well-accepted by most cats, and has a robust safety profile2. It is also a winner of an ISFM Easy to Give Award.
Elanco's Veterinary Technical Consultant, Lepha McCartan said: "It is very exciting to be launching this new indication for Onsior because musculoskeletal disorders are commonplace in cats.
"Although reports vary, studies have shown that radiographic evidence of DJD has a prevalence as high as over 90%.3
"At Elanco we are passionate about keeping cats doing what they love and Onsior enables this while also giving vets more choice for managing chronic musculo-skeletal disease."
For more information, visit: myelanco.co.uk or speak to your Elanco territory manager.
In trials, Credelio killed more than 98% of ticks within 24 hours1, and more than 99% of fleas within 12 hours with all fleas killed within 24 hours, for one month2.
Credelio is available in two vanilla-yeast-flavoured tablet strengths and is approved for kittens and cats from 8 weeks of age and older and 0.5 kilograms or heavier.
The tablets are well-accepted by cats: in a three-month field study pet owners were 100% successful in administering the product, replicated each consecutive month3.
Elanco says the new product will be of particular interest to the one in three cat owners who currently use a topical spot on or collar that - according to its research - would prefer to give their cat a tablet when it comes to tick and flea control4.
Victoria Sumpter, Companion Animal Technical Marketing Manager at Elanco UK & Ireland said: "Not only can it be stressful to give a tick and flea treatment to a cat, it can completely disrupt a cat’s daily routine.
"With Credelio, treating a cat for ticks and fleas doesn’t have to be a big to-do. The chewable, vanilla-yeast flavoured tablets are widely accepted by cats, so owners have the flexibility to treat with or immediately after food in a way that suits their cat’s needs."
For more information, visit: www.credelio.co.uk
The company says it recognises how frustrating it can be for veterinary surgeons if the owner doesn't recognise that their dog has a painful condition. This can be compounded by short consult times, leaving vets unable to fully communicate the implications and treatment options for the disease.
In the video, Zoe encourages vets to tailor their language to each case, in particular, using the language dog owners will use.
While undertaking her research Zoe noticed that many owners do not talk about OA in the same way that vets might; instead of referring to lameness or pain, many owners will refer to the actual physical signs of OA such as stiffness or communicate that their dog is slowing down.
Zoe has also warned that not all owners are convinced by visual demonstrations such as flexing and extending the dogs joints. Instead, she suggests encouraging the owner to get hands-on.
Zoe said: "Point out the visual changes suggestive of osteoarthritis that you can see, such as muscle loss, scuffed nails, and enlarged joints. And encourage them to have a look and a feel, comparing affected and unaffected joints. Hopefully, the owner may be more receptive to the conversation now they associate it with a symptom they can recognise."
Zoe says she also finds that many owners of older dogs often misinterpret the signs of OA as 'just old age' and may not be aware that the condition can be managed effectively with medication, the right exercise, diet and by making modifications in the home.
Elanco has also produced an OA management template which enables both the vet and the owner to create a tailored plan. It provides the owner with information to take away with them about how to modify their home, written in collaboration with Founder of Canine Arthritis Management, Hannah Capon.
Lastly, Zoe recommends a whole practice approach to becoming experts on OA, veterinary nurses in particular. She said: "Vet nurses often have great ideas about how to explain the condition in a way that owners understand. Better owner understanding of OA should lead to better adherence to treatment plans and ultimately better clinical outcomes."
To watch the video, click here.
To access the suite of assets Elanco has created for Onsior (which includes the management plan, social media posts for the practice, and infographic to help owners to spot the signs of OA) visit: www.myelanco.co.uk